[{"orgOrder":0,"company":"Exscientia","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DSP-0038","moa":"5-HT1A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Sumitomo Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ ALS Association","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ ALS Association"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Ensysce Biosciences"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Nafamostat Hcl","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Ensysce Biosciences"},{"orgOrder":0,"company":"Argent BioPharma","sponsor":"Sputnik Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Argent BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Argent BioPharma \/ Sputnik Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Argent BioPharma \/ Sputnik Enterprises"},{"orgOrder":0,"company":"Argent BioPharma","sponsor":"Sputnik Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Argent BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Argent BioPharma \/ Sputnik Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Argent BioPharma \/ Sputnik Enterprises"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Brigham and Women's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Brigham and Women's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Brigham and Women's Hospital"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Foralumab","moa":"CD3","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"NodThera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NT-0796","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"NodThera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NodThera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/ Inapplicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Emplicure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Tablet, Extended Release","sponsorNew":"Quotient Sciences \/ Emplicure","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Emplicure"},{"orgOrder":0,"company":"Inoviv","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"HER-096","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Inoviv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inoviv \/ Hoxton Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Inoviv \/ Hoxton Ventures"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MTX325","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"MTX325","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Mission Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Oxycodone Prodrug,Nafamostat Hydrochloride

                          Therapeutic Area : Neurology

                          Study Phase : Phase I

                          Sponsor : Ensysce Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : The collaboration aims to examine and evaluate the full commercial dose range of the PF614-MPAR drug product, the combination of PF614 with the trypsin inhibitor nafamostat, to treat chronic pain.

                          Product Name : PF614-MPAR

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          May 20, 2024

                          Lead Product(s) : Oxycodone Prodrug,Nafamostat Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Ensysce Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Quotient

                          02

                          Lead Product(s) : Oxycodone Prodrug,Nafamostat

                          Therapeutic Area : Neurology

                          Study Phase : Phase I

                          Sponsor : Ensysce Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : PF614-MPAR (oxycodone prodrug) binds and inhibits adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability, thus reduces severe pain. It is the first opioid drug product that has both abuse deterrent properties as well as overdose pr...

                          Product Name : PF614-MPAR

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 25, 2023

                          Lead Product(s) : Oxycodone Prodrug,Nafamostat

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Ensysce Biosciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Quotient

                          03

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Neurology

                          Study Phase : Phase I

                          Sponsor : Emplicure

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Details : Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.

                          Product Name : Empli03

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          November 29, 2022

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Emplicure

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Quotient

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Anti-CD3 antibody TZLS-401 intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, being developed for amyotrophic lateral sclerosis.

                          Product Name : TZLS-401

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 04, 2025

                          Lead Product(s) : Foralumab

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proceeds from the placement will support the advancement of the Argent drug development pipeline, focusing on the progress of CannEpil (Cannabidiol) in treating refractory epilepsy.

                          Product Name : CannEpil

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          January 07, 2025

                          Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Sputnik Enterprises

                          Deal Size : $4.5 million

                          Deal Type : Private Placement

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proceeds from the placement will support the advancement of the Argent drug development pipeline, focusing on the progress of CannEpil (Cannabidiol) in treating refractory epilepsy.

                          Product Name : CannEpil

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          January 06, 2025

                          Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Sputnik Enterprises

                          Deal Size : $4.5 million

                          Deal Type : Private Placement

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, which is being evaluated for the treatment of neuropathic corneal pain.

                          Product Name : OK-101

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          November 07, 2024

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, which is being evaluated for the treatment of neuropathic corneal pain.

                          Product Name : OK-101

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          September 02, 2024

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The funding aims to support the company's investigattional product MTX325 brain-penetrant USP30 inhibitor. It is being evaluated in early-stage studies for the treatment of Parkinson's disease.

                          Product Name : MTX325

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 07, 2024

                          Lead Product(s) : MTX325

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                          Deal Size : $5.2 million

                          Deal Type : Funding

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The net proceeds will be used to accelerate company's drug development pipelines, including HER-096, developed from neurotrophic factor CDNF, a groundbreaking approach to Parkinson's disease.

                          Product Name : HER-096

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          January 30, 2024

                          Lead Product(s) : HER-096

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Hoxton Ventures

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank